Spring
Accelerating drug discovery with AI
Spring built AI tools that gave scientists genuine superpowers to discover new cures. From big pharma to rare disease orgs to academia, our platform closed the long-standing gap between scientific and computational teams, arming both with the most insightful image analysis suite in the industry.
We pioneered AI-driven analysis over segmentation and put cutting-edge tools using technique like cell painting directly in the hands of scientists, embracing AI workflows that honored biology’s complexity.
Customers responded by abandoning competitors and converting from pilots to paying subscribers at the rate of over 90%.
Scientists needed high‑content imaging they could use directly without computational intermediaries but the workflows were complex and error‑prone. The design challenge was to translate intricate ML processes into an intuitive, scientist‑friendly interface and embed safeguards against overfitting, batch effects, and inconsistent assay design without adding friction.
Spring’s solution blended powerful defaults like Z‑score normalization and plate layout guidance with proprietary LLM‑driven, context‑aware insights and always‑visible key scientific variables. This combination let scientists trust their results, move quickly, and confidently explore new hypotheses.
After years of delivering technology loved by bioscientists and data scientists uncovering unknown drug mechanisms and enabling large‑scale hypothesis generation, Spring’s platform has been acquired by a major Bay Area biotech, where it will reach more scientists than ever.
Design
JJ Moi
Development
Ben Komalo / Brandon White / Michael Wiest
Science
Rachel Jacobson / Daniel Chen / Hope O'donnell / Francesci Rubbo
Further Readings
→ Accelerating the discovery of therapies for aging and its related diseases
→ COVID-19 is the latest disease to point at our need to treat immune aging
